Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA

Journal of Controlled Release

Volumn 171, Issue 3, 2013, Pages 349-357

  Taratula, Oleh ^a,b   Kuzmov, Andriy ^a   Shah, Milin ^a   Garbuzenko, Olga B ^a   Minko, Tamara ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

(LHRH); Drug resistance; Imaging; Inhalation; Luteinizing hormone releasing hormone; Nanostructured lipid carrier; Orthotopic lung cancer model

Indexed keywords

BIOLOGICAL ORGANS; CELL MEMBRANES; CELLS; CYTOLOGY; DISEASES; DRUG INTERACTIONS; DRUG PRODUCTS; DRUG THERAPY; IMAGING TECHNIQUES; MEDICAL NANOTECHNOLOGY; RESPIRATORY SYSTEM; TUMORS;

(LHRH); DRUG RESISTANCE; INHALATION; LUNG CANCER; LUTEINIZING HORMONE RELEASING HORMONES; NANOSTRUCTURED LIPID CARRIERS;

TARGETED DRUG DELIVERY;

DOXORUBICIN; GONADORELIN; GONADORELIN RECEPTOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; NANOCARRIER; PACLITAXEL; PROTEIN BCL 2; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; BODY DISTRIBUTION; CANCER CELL; CANCER RESISTANCE; CELL MEMBRANE; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ECHOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHALATION; LUNG; LUNG CANCER; LUNG PARENCHYMA; MOUSE; NANOMEDICINE; NEBULIZATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; WHOLE BODY SCANNER; ZETA POTENTIAL;

DRUG RESISTANCE; IMAGING; INHALATION; LUTEINIZING HORMONE-RELEASING HORMONE (LHRH); NANOSTRUCTURED LIPID CARRIER; ORTHOTOPIC LUNG CANCER MODEL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; GONADOTROPIN-RELEASING HORMONE; HUMANS; LIPIDS; LUNG; LUNG NEOPLASMS; MICE; MICE, NUDE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NANOSTRUCTURES; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING;

EID: 84892675615     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.04.018     Document Type: Article

References (44)

1. D.P. Carbone, E. Felip, Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms, Clin. Lung Cancer 12 (2011) 261-271.
2. H. Francis, B. Solomon, The current status of targeted therapy for non-small cell lung cancer, Intern. Med. J. 40 (2010) 611-618.
3. M.J. Higgins, D.S. Ettinger, Chemotherapy for lung cancer: the state of the art in 2009, Expert. Rev. Anticancer. Ther. 9 (2009) 1365-1378.
4. J.A. Katzel, M.P. Fanucchi, Z. Li, Recent advances of novel targeted therapy in non-small cell lung cancer, J. Hematol. Oncol. 2 (2009) 2.
5. T.D. Wagner, G.Y. Yang, The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC), Curr. Drug Targets 11 (2010) 67-73.
6. T.C. Carvalho, S.R. Carvalho, J.T. McConville, Formulations for pulmonary administration of anticancer agents to treat lung malignancies, J. Aerosol Med. Pulm. Drug Deliv. 24 (2011) 61-80.
7. C.L. Densmore, The re-emergence of aerosol gene delivery: a viable approach to lung cancer therapy, Curr. Cancer Drug Targets 3 (2003) 275-286. (Pubitemid 36944261)
8. A. Gautam, N. Koshkina, Paclitaxel (taxol) and taxoid derivates for lung cancer treatment: potential for aerosol delivery, Curr. Cancer Drug Targets 3 (2003) 287-296. (Pubitemid 36944262)
9. N.V. Koshkina, J.C. Waldrep, V. Knight, Camptothecins and lung cancer: improved delivery systems by aerosol, Curr. Cancer Drug Targets 3 (2003) 251-264. (Pubitemid 36944259)
10. R.I. Pakunlu, T.J. Cook, T. Minko, Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin, Pharm. Res. 20 (2003) 351-359. (Pubitemid 36288363)
11. R.I. Pakunlu, Y. Wang, W. Tsao, V. Pozharov, T.J. Cook, T. Minko, Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system, Cancer Res. 64 (2004) 6214-6224. (Pubitemid 39129423)
12. L. Amaral, H. Engi, M. Viveiros, J. Molnar, Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents, In Vivo 21 (2007) 237-244. (Pubitemid 46534275)
13. V. Merino, N.V. Jimenez-Torres, M. Merino-Sanjuan, Relevance ofmultidrug resistance proteins on the clinical efficacy of cancer therapy, Curr. Drug Deliv. 1 (2004) 203-212.
14. R. O'Connor, The pharmacology of cancer resistance, Anticancer Res. 27 (2007) 1267-1272. (Pubitemid 46813088)
15. T. Ozben, Mechanisms and strategies to overcome multiple drug resistance in cancer, FEBS Lett. 580 (2006) 2903-2909. (Pubitemid 43729172)
16. R.I. Pakunlu, Y. Wang, M. Saad, J.J. Khandare, V. Starovoytov, T. Minko, In vitro and in vivo intracellular liposomal delivery of antisense oligonucleotides and anticancer drug, J. Control. Release 114 (2006) 153-162. (Pubitemid 44291853)
17. M. Saad, O.B. Garbuzenko, T. Minko, Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer, Nanomedicine 3 (2008) 761-776.
18. P. Chandna, J.J. Khandare, E. Ber, L. Rodriguez-Rodriguez, T. Minko, Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers, Pharm. Res. 27 (2010) 2296-2306.
19. S.S. Dharap, Y. Wang, P. Chandna, J.J. Khandare, B. Qiu, S. Gunaseelan, P.J. Sinko, S. Stein, A. Farmanfarmaian, T. Minko, Tumor-specific targeting of an anticancer drug delivery systemby LHRH peptide, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12962-12967. (Pubitemid 41279472)
20. O. Taratula, O.B. Garbuzenko, P. Kirkpatrick, I. Pandya, R. Savla, V.P. Pozharov, H. He, T. Minko, Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery, J. Control. Release 140 (2009) 284-293.
21. O. Taratula, O. Garbuzenko, R. Savla, Y.A. Wang, H. He, T. Minko, Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes, Curr. Drug Deliv. 8 (2011) 59-69.
22. O. Taratula, O.B. Garbuzenko, A.M. Chen, T. Minko, Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA, J. Drug Target. 19 (2011) 900-914.
23. O.B. Garbuzenko, M. Saad, S. Betigeri, M. Zhang, A.A. Vetcher, V.A. Soldatenkov, D.C. Reimer, V.P. Pozharov, T. Minko, Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug, Pharm. Res. 26 (2009) 382-394.
24. R. Kuruba, A. Wilson, X. Gao, S. Li, Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation, AAPS J. 11 (2009) 23-30.
25. M. Uner, Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems, Pharmazie 61 (2006) 375-386. (Pubitemid 43724410)
26. P.M. Conn, E. Hazum, Luteinizing hormone release and gonadotropin- releasing hormone (GnRH) receptor internalization: independent actions of GnRH, Endocrinology 109 (1981) 2040-2045. (Pubitemid 12252331)
27. M. Saad, O.B. Garbuzenko, E. Ber, P. Chandna, J.J. Khandare, V.P. Pozharov, T. Minko, Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging? J. Control. Release 130 (2008) 107-114.
28. M. Zhang, O.B. Garbuzenko, K.R. Reuhl, L. Rodriguez-Rodriguez, T. Minko, Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases, Nanomedicine 7 (2012) 185-197.
29. Z.R. Huang, S.C. Hua, Y.L. Yang, J.Y. Fang, Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion, Acta Pharmacol. Sin. 29 (2008) 1094-1102.
30. X. Li, S.F. Nie, J. Kong, N. Li, C.Y. Ju, W.S. Pan, A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers, Int. J. Pharm. 363 (2008) 177-182.
31. X.G. Zhang, J. Miao, Y.Q. Dai, Y.Z. Du, H. Yuan, F.Q. Hu, Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells, Int. J. Pharm. 361 (2008) 239-244.
32. P. Chandna, M. Saad, Y. Wang, E. Ber, J. Khandare, A.A. Vetcher, V.A. Soldatenkov, T. Minko, Targeted proapoptotic anticancer drug delivery system, Mol. Pharm. 4 (2007) 668-678. (Pubitemid 350004266)
33. M.L. Patil, M. Zhang, S. Betigeri, O. Taratula, H. He, T. Minko, Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery, Bioconjug. Chem. 19 (2008) 1396-1403. (Pubitemid 352032339)
34. O.B. Garbuzenko, M. Saad, V.P. Pozharov, K.R. Reuhl, G. Mainelis, T. Minko, Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 10737-10742.
35. G. Mainelis, S. Seshadri, O.B. Garbuzenko, T. Han, Z. Wang, T. Minko, Characterization and application of a nose-only exposure chamber for inhalation delivery of liposomal drugs and nucleic acids to mice, J. Aerosol Med. Pulm. Drug Deliv. 20 (Mar 26 2013), (Epub ahead of print).
36. T. Minko, P. Kopeckova, J. Kopecek, Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma, Int. J. Cancer 86 (2000) 108-117. (Pubitemid 30133995)
37. S. Betigeri, M. Zhang, O. Garbuzenko, T. Minko, Non-viral systemic delivery of siRNA or antisense oligonucleotides targeted to Jun N-terminal kinase 1 prevents cellular hypoxic damage, Drug Deliv. Transl. Res. 1 (2011) 13-24.
38. Y. Wang, M. Saad, R.I. Pakunlu, J.J. Khandare, O.B. Garbuzenko, A.A. Vetcher, V.A. Soldatenkov, V.P. Pozharov, T. Minko, Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor, Clin. Cancer Res. 14 (2008) 3607-3616.
39. J.J. Khandare, P. Chandna, Y. Wang, V.P. Pozharov, T. Minko, Novel polymeric prodrug withmultivalent components for cancer therapy, J. Pharmacol. Exp. Ther. 317 (2006) 929-937. (Pubitemid 43764094)
40. S.S. Dharap, B. Qiu, G.C. Williams, P. Sinko, S. Stein, T. Minko, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, J. Control. Release 91 (2003) 61-73. (Pubitemid 37288877)
41. S.S. Dharap, T. Minko, Targeted proapoptotic LHRH-BH3 peptide, Pharm. Res. 20 (2003) 889-896. (Pubitemid 36628435)
42. F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, D.A. Gewirtz, Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells, Mol. Pharmacol. 45 (1994) 649-656. (Pubitemid 24139191)
43. R.L. Momparler, M. Karon, S.E. Siegel, F. Avila, Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells, Cancer Res. 36 (1976) 2891-2895.
44. O. Bagasra, K.R. Prilliman, RNA interference: the molecular immune system, J. Mol. Histol. 35 (2004) 545-553. (Pubitemid 41404640)